unifiram
Selected indexed studies
- Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals. (Drugs, 2022) [PMID:35366192]
- Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers. (CNS Drug Rev, 2006) [PMID:16834757]
- Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings. (J Enzyme Inhib Med Chem, 2016) [PMID:25831025]
_Worker-drafted node — pending editorial review._
Connections
unifiram protects against
Sources
- Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers. (2006) pubmed
- Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs. (2004) pubmed
- Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings. (2016) pubmed
- Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators. (2008) pubmed
- Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals. (2022) pubmed
- Enantioselective synthesis and preliminary pharmacological evaluation of the enantiomers of unifiram (DM232), a potent cognition-enhancing agent. (2005) pubmed
- AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram). (2003) pubmed
- Substituted piperazines as nootropic agents: 2- or 3-phenyl derivatives structurally related to the cognition-enhancer DM235. (2015) pubmed
- Unused drugs returned to the pharmacy--new data. (2001) pubmed
- Design, synthesis, and preliminary pharmacological evaluation of 1, 4-diazabicyclo[4.3.0]nonan-9-ones as a new class of highly potent nootropic agents. (2000) pubmed